Safety is the biggest concern for the FDA. How effective TPM opioid patches are is very much secondary to them. This means more testing IMO pre and post approval to be able to market the product as a safer alternative.
Ann: FDA meeting provides guidance for TPM/Oxymorphone patch, page-4
-
- There are more pages in this discussion • 55 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.507M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $6 | 1.963K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 51 | 93002619 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 60312650 | 22 |
View Market Depth
| Last trade - 09.59am 23/08/2024 (20 minute delay) ? |
| AVE (ASX) Chart |